



Minnesota Insulin Safety Net Program (Program): Frequently Asked Questions for Pharmacists (June 30, 2020)

In 2020, the Minnesota Legislature passed the **Alec Smith Insulin Affordability Act**, which Governor Tim Walz signed into law on April 15, 2020. The Act creates an Insulin Safety Net Program that will aid individuals who can't afford insulin.

The urgent need part of the program allows eligible individuals who are in urgent need of insulin to get a one-time, 30-day supply of insulin from their pharmacy, for a \$35 co-pay. An emergency supply can normally be obtained only once in a 12-month period. However, there is an option for some individuals to receive a second 30-day supply in certain circumstances. The insulin manufacturer will reimburse the pharmacy for the insulin or send the pharmacy a replacement supply.

The continuing need part of the program requires manufacturers to provide insulin to eligible individuals for up to one year, with the option to renew annually. The manufacturers will have to provide up to a 90-day supply of insulin for a co-pay of no more than \$50. Some individuals with insurance may be referred to a manufacturer's co-pay program, which waives all or part of the co-pay that the patient normally has to pay, if the co-pay program provides you a better value.

This document answers questions about the program that the Board anticipates it will receive frequently from pharmacists and pharmacies. It may be updated from time-to-time, if other questions are received. Pharmacists can also review separate documents that have been prepared for patients and pharmaceutical manufacturers. All of these documents can be found at: <https://mn.gov/boards/pharmacy/insulinsafetynetprogram/> and will be updated as needed.

QUESTIONS FOR PHARMACIES

Q: When does the Minnesota Insulin Safety Net Program go into effect?

A: It goes into effect on July 1, 2020.

Q: What types of insulin are covered?

A: Most insulins that are dispensed by community pharmacies will be covered. Insulins not covered include:

- A few insulins that are used only within hospitals;

- Products made by smaller insulin manufacturers; and
- *Relatively* inexpensive insulins that pharmacies can usually purchase for less than \$8.00 per milliliter.

Q: Is my pharmacy required to participate in the Minnesota Insulin Safety Net Program?

A: If your pharmacy is located within Minnesota and is licensed in the community/outpatient category, it **must** participate in the Minnesota Insulin Safety Net Program. A pharmacist may refuse to fill a clinically and legally valid insulin prescription that would be covered under the program only if:

- The pharmacy does not have the insulin in stock;
- The application for the Urgent Need Program is not correctly filled out and signed; or
- The patient refuses to pay the co-pay.

If a pharmacy does not have the insulin in stock, the pharmacist should determine if the patient can wait until the pharmacy obtains the insulin. If not, the pharmacist should assist the patient in locating another nearby pharmacy that does have the insulin in stock.

Q: Who is eligible to receive insulin in an urgent need situation?

A: To be eligible for the urgent need program a patient must:

- Live in Minnesota
- Have an urgent need for insulin. An urgent need for insulin means that the patient has less than a 7-day supply of insulin and will likely have significant health consequences if they run out of insulin.
- Pay more than \$75 each month for their insulin.
- Not be enrolled in Medical Assistance or MinnesotaCare.
- Present identification proving Minnesota residency in the form of a valid Minnesota identification card, driver's license or permit, or tribal-issued identification. If they are a minor under the age of 18, their parent or legal guardian must provide the pharmacy with proof of residency.

A patient can normally access an urgent-need insulin supply only once in a 12-month period. However, if they are waiting for your Medical Assistance or MinnesotaCare coverage to begin, or if they have been determined ineligible for a manufacturer's patient assistance program by the manufacturer and are waiting for the Minnesota Board of Pharmacy's decision on an appeal, they may be eligible to access a second 30-day supply.

Q: How often can a patient receive a 30-day urgent need supply of insulin?

A: A patient can only receive a 30-day urgent need supply of insulin only once every 12 months, *unless* one of the following applies:

- The patient has applied for medical assistance or MinnesotaCare but has not been determined eligible or has been determined eligible, but their coverage is not yet effective; or
- A manufacturer has determined the patient is ineligible for its continuing need safety net program, the patient has asked the Board to do an eligibility review, and the Board has not yet made a decision about the request.

Q: If a patient meets one of the exceptions for getting a second, 30-day supply of urgent need insulin, what does the patient need to do to get the insulin?

A: Fill out another Insulin Safety Net Program Application that is available:

- On www.MNinsulin.org;
- From pharmacies; and
- May also be available at clinics, hospital emergency departments, and urgent care clinics.
- Bring the completed, signed, and dated application form to a pharmacy. (Or fill one out at the pharmacy). There are questions on the application that ask which of the two exceptions applies.
- Bring along a prescription for insulin (unless a prescription with refills is already on file with the pharmacy). The patient needs a prescription even if the insulin can normally be purchased without a prescription.
- Provide the pharmacy with identification that shows Minnesota residency. A patient can use a:
 - Valid Minnesota driver's license;
 - Valid Minnesota identification card;
 - Valid tribal identification card from a Minnesota tribe; or
 - If the person who needs insulin is under the age of 18, the parent or legal guardian must provide proof of residency.

Q: Does the pharmacy have to verify any information on the application for the urgent need program?

A: By signing the application, the patient will attest to the accuracy of the information. Therefore, the only thing that has to be checked is the identification that verifies Minnesota residency. A pharmacy technician may check the ID to verify it. (*Special note – for the duration of any COVID-19 Peacetime Emergency declared by the Governor, pharmacies may accept an expired ID card*).

Q: How will I know if the patient has already received a 30-day, urgent need supply of insulin within the past 12 months?

A: If manufacturers reimburse pharmacies for the actual acquisition cost of the insulin, they may do so by using a claims adjudicator. In that case, the adjudicator will most likely reject a claim submitted by the pharmacy if the patient has received a 30-day urgent need supply during the previous 12 months. The pharmacy will need to get an override of the rejection if the patient is allowed to receive a second, 30-day supply of insulin due to one of the two exceptions mentioned above.

If a manufacturer sends a replacement supply of insulin, the pharmacy would not know if the patient received an urgent need supply of insulin from a different pharmacy. In that case, pharmacies should still dispense the insulin if the patient has submitted a completed and signed application, attesting to the fact that they have not received an urgent need supply within the last 12 months. Manufacturers must reimburse the pharmacy or send a replacement supply, even if the patient has received an urgent need supply within the previous 12 months.

Q: In general, how will the pharmacy be reimbursed for the cost of the insulin dispensed? (See questions below for information concerning specific manufacturers).

A: The law requires the manufacturer to reimburse the pharmacy for its actual acquisition cost – or to send a replacement supply of insulin to the pharmacy.

- If the manufacturer decides to reimburse the pharmacy, the claims must be processed using National Council for Prescription Drug Program (NCPDP) standards for electronic claims processing. One way the manufacturer could do that is to use a claims adjudicator. The manufacturer can't require pharmacies to submit paper claims.
 - Pharmacies should submit a claim using their *actual acquisition cost* (AAC) for the insulin dispensed. If the submitted amount exceeds the National Average Drug Acquisition Cost (NADAC) for the amount of insulin dispensed, pharmacies should have documentation that AAC did exceed NADAC.
 - Pharmacies should *not* submit a dispensing fee because manufacturers are only required to reimburse pharmacies for the actual acquisition cost of the insulin. *However, pharmacies are allowed to retain the entire \$35 copayment made by the patient.*
 - Based on current practices for reimbursement for claims submitted by pharmacies, it is reasonable for manufacturers to make sure that pharmacies are reimbursed within 14 days.

Q: In general, can the manufacturer send a replacement supply of insulin to the pharmacy, rather than reimbursing the pharmacy for the cost? (See questions below for information concerning specific manufacturers).

A: The law allows manufacturers to send to the pharmacy a replacement supply of the same insulin, in the amount dispensed. The law does not specify how quickly the manufacturer must send the replacement supply. However, the Board believes that it is reasonable for manufacturers to send a replacement supply within 14 days of receiving required documentation from the pharmacy. The required documentation can include a copy of the application submitted by the patient and a copy of the prescription that was filled. The pharmacy will most likely want to send some sort of form requesting that the insulin be replaced. The manufacturers may also develop a form that pharmacies will have to use.

Q: Where can pharmacists find out information about how Eli Lilly will handle urgent need claims for their products?

A: If you are a pharmacist in the State of Minnesota dispensing urgent need product for the Minnesota Insulin Safety Net Program, visit <http://www.voucheraccess.com>. Pharmacies may either be given a voucher to use for reimbursement or be given information on how a replacement supply will be sent to the pharmacy.

Q: Where can pharmacists find out information about how Novo Nordisk will handle urgent need claims for their products?

A: Pharmacists may request an urgent need Voucher by calling **1-866-310-7549**. Upon processing the voucher, they will be reimbursed for the urgent need insulin dispensed to the patient. Instructions for processing the voucher may be found within the “Pharmacist” section in the Program’s Terms and Conditions <https://www.novocare.com/eligibility/pap-voucher.html>. For reimbursement, please submit electronically to SS&C Health using the BIN, PCN, GRP and ID provided. Reimbursement will be received from SS&C Health. **For any processing assistance regarding SS&C Health online processing, please call the Pharmacist Help Desk at 1-844-373-0987.** Given that Novo Nordisk will be reimbursing pharmacies for insulin dispensed under the Urgent Need Program, Novo Nordisk will not provide pharmacies with replacement stock.

Q: Where can pharmacists find out information about how Sanofi will handle urgent need claims for their products?

A: If you are a pharmacist in the State of Minnesota dispensing urgent need product for the Minnesota Insulin Safety Net Program, you will access an online portal where you will receive a voucher ID# to be used when adjudicating each patient’s prescription. Sanofi has provided the following, detailed instructions to the Board.



Minnesota Urgent Need Safety Net Program Pharmacy Instructions for Submitting a Claim for Reimbursement

Sanofi is pleased to provide a program as part of the Alec Smith Insulin Affordability Act (HF 3100) in the State of Minnesota. To submit an electronic claim for reimbursement, please follow the steps below to process claims for patients who meet the eligibility criteria for the MN Urgent Need Safety Net Program.

STEP 1: Visit the following website: www.activatedthecard.com/7925 and enter your pharmacy's NCPDP number:

The screenshot shows the Sanofi logo at the top left. Below it, the text "Minnesota Urgent Need Safety Net Program" is centered. A message reads: "To access the site please enter your 7-digit NCPDP number and click NEXT." Below this is a text input field labeled "* NCPDP Number" with a placeholder "XXXXXXX". A blue "NEXT" button is positioned below the field. At the bottom left, there is a small asterisk and the word "Required".


STEP 2: Please attest to the 2 statements on the screen:

The screenshot shows the Sanofi logo at the top left. Below it, the text "Minnesota Urgent Need Safety Net Program" is centered. A message reads: "Please attest to the following statements:". Below this is a text input field containing two statements: "My pharmacy is located in the state of MN*" and "Patient met all criteria set forth in the Alec Smith Insulin Affordability Act*". Each statement has radio buttons for "YES" and "NO". A blue "NEXT" button is positioned below the field. At the bottom left, there is a small asterisk and the word "Required". At the bottom of the page, there is a small copyright notice: "© 2020 Sanofi across U.S. LLC. All rights reserved."

STEP 3: After a successful attestation, please select the Sanofi product prescribed to the patient applicant for which you are submitting a claim:

The screenshot shows a message: "Please select a product to obtain a voucher and submit your claim for reimbursement*". Below this are four product logos: APIDRA (multiple injection 100 U/ml), Admelog (insulin lispro injection 100 U/ml), LANTUS (insulin glargine injection 100 U/ml), and Toujeo (insulin glargine injection 300 U/ml). Below the logos, there is a small asterisk and the text "Please select a product".

STEP 4: Once attestation and product selection are complete, a patient-specific e-voucher will be provided. Please process the claim according to the instructions on the product-specific e-voucher. See below sample voucher for example purposes only.



If you have any issues or further questions, please contact the Help Desk at **1-800-657-7613**

© 2020 sanofi-aventis U.S. LLC. All rights reserved. MAT-US-2014096 07/2020

Q: Who is eligible to receive insulin on a continuing need basis?

A: To be eligible to receive insulin on a continuing basis, persons must:

- Be a resident of Minnesota.
- Have a family income that is equal to or less than 400 percent of the federal poverty guidelines income
- **Not** be enrolled in Medical Assistance or MinnesotaCare
- **Not** be eligible to receive health care through **most** federally funded programs
 - However, an individual who is enrolled in Medicare Part D **is eligible** for a manufacturer's patient assistance program if the individual has spent \$1,000 on prescription drugs in the current calendar year and meets the other eligibility requirements
- **Not** be eligible to receive prescription drug benefits through the Department of Veterans Affairs

Persons who have insurance that covers drugs **may** be eligible to receive an urgent supply of insulin. However, if they pay \$75 or less in out-of-pocket costs, for a 30-day supply of insulin, they are **not** eligible. (Out-of-pockets costs include co-payments, coinsurance, and deductibles).

Q: Am I required to determine if a patient is eligible to receive insulin for the continuing need portion of the program?

A: No, pharmacies *are not* required to determine eligibility for the continuing need safety net program. Patients need to apply through the insulin manufacturer.

Q: How will people get enrolled in the continuing need safety net program?

A: Persons need to apply through the insulin manufacturer. The manufacturer must respond to the application within a certain period of time. If the manufacturer decides a person is eligible, it will send them an eligibility statement, which will be valid for 12 months.

- The eligibility statement might be in the form of a card that has the information that a pharmacy will need when it fills prescriptions.
- However, the law does not say how the eligibility statement needs to be prepared. So, the manufacturer might send a letter instead.

Q: In general, how will a patient obtain a continuing need supply of insulin? (*See questions below for information concerning specific manufacturers*).

A: A manufacturer is allowed to ship insulin directly to a patient's home. If a manufacturer chooses that option, the patient will not interact with community/outpatient pharmacies located in Minnesota.

If a manufacturer does not ship insulin directly to a patient's home, patients need to provide the pharmacy with the statement of eligibility or card that they received from the manufacturer. They will also need to give the pharmacy a prescription for insulin (unless the pharmacy already has a prescription on file for the patient). The FAQ document that the Board has prepared for patients recommends that they work with their pharmacy at least a couple weeks in advance of when they will run out of insulin.

- The pharmacy needs to submit an order to the manufacturer for a 90-day supply of the insulin that was prescribed. The manufacturer should provide information to pharmacies about how to submit the order. The pharmacy must include with the order to the manufacturer the following information:
 - the pharmacy's name and shipping address;
 - office telephone number, fax number, e-mail address, and contact name; and
 - any specific days or times when deliveries are not accepted by the pharmacy.
- The manufacturer will ship the insulin to the pharmacy so that the patient can pick it up. It may take a couple of weeks for the insulin to be shipped to the pharmacy.
- The insulin should be labeled as any other dispensed drug would be labeled.

- The pharmacy is not allowed to charge the patient for the cost of the insulin, but is allowed to collect a copayment of up to \$50 for each 90-day supply of insulin that is dispensed.
- The pharmacy is not allowed to bill any insurance that the patient might have. (This does not apply if the patient has been enrolled in one of the manufacturer’s copay assistance programs, rather than Minnesota’s continuing need program).
- This process needs to be completed for each 90-day supply of insulin that the patient receives.

Note that as an alternative, the Board will allow manufacturers to establish a process through which pharmacies can dispense the insulin from the pharmacies inventory and submit a claim to a claims adjudicator. However, manufacturers will not be required to do that.

Q: What information is available for the Eli Lilly Continuing Need program?

A: The Lilly Minnesota Patient Assistance Program (“Program”) provides insulin to qualifying individuals for 12 months during the patient’s enrollment in the Program. ***The individual’s pharmacy must order insulin from the Program. Insulin is shipped to the enrolled individual’s pharmacy upon receipt of the order. Patient’s can obtain information and apply for the Eli Lilly Continuing Need program by calling the Lilly Minnesota Patient Assistance Program at 855-447-8412.***

Q: What information is available for the Novo Nordisk Continuing Need program

A: Novo Nordisk has decided that eligible patients in the Minnesota Insulin Safety Net Program who qualify to receive insulin on a continuing need basis will have their free insulin shipped directly to their home, as allowed by law.

Q: What information is available for the Sanofi Continuing Need program?

A: Sanofi has decided that eligible patients in the Minnesota Insulin Safety Net Program who qualify to receive insulin on a continuing need basis will have their free insulin shipped directly to their home, as allowed by law.

Q: Does a pharmacist have to fill prescriptions for the Program if the pharmacist has valid clinical concerns?

A: For any prescription, pharmacists must conduct patient profile and drug utilization reviews. If, in the pharmacist’s professional judgment, the patient might be harmed if the insulin was dispensed as prescribed, the pharmacist is not required to fill the prescription. The pharmacist should contact the prescriber to resolve the clinical concerns as soon as possible.

DESCRIPTION OF INSULIN MANUFACTURER PROGRAMS

This section provides detailed information about the Minnesota continuing need program of each of the manufacturers. Each of the insulin manufacturers also offers other assistance programs and information is also provided about them. This section was developed for patients but may also be useful to pharmacists. The following information was developed in June 2020 and was accurate as of that month. The Board will update this data regularly.

Eli Lilly

Eli Lilly has provided the Board with the following information concerning their ***Minnesota continuing need program***:

To learn more about the Eli Lilly Minnesota continuing need program and to apply for the program, please call the Lilly Minnesota Patient Assistance Program at 855-447-8412 or visit the Lilly Minnesota Safety Net Program website at - <https://www.lilly.com/resources/minnesota-insulin-safety-net-program>.

- You must call the hotline or visit the website listed above to obtain an application.
- Follow the instructions provided to apply for the program.
- You will be notified by letter if you are qualified for and enrolled in the program.
- If you are enrolled, the letter will include instructions for the next steps you need to take.
 - You will need to take the letter to your pharmacy
 - You will also need to bring a prescription for the insulin to the pharmacy, unless that pharmacy already has a prescription on file for you.
 - Eli Lilly will ship the insulin to your pharmacy so that you can pick it up.

In addition to the program that Eli Lilly has created for the Minnesota Insulin Safety Net Program, it offers the following assistance:

Lilly Diabetes Solution Center

Anyone who uses Lilly insulin and needs help with diabetes care can call the Lilly Diabetes Solution Center. A live representative will have a confidential conversation and present solutions that are based on each person's circumstances. The helpline is available Monday through Friday, from 9 am to 8 pm, ET. **Call 1-833-808-1234, M-F, 9 am-8 pm, ET.**

Non-branded Insulin

Lilly now sells a portfolio of non-branded insulins, a possible substitute for their branded alternatives. It may be less expensive for persons who have no insurance. However, for many commercially insured patients, the branded insulins may still be less expensive than Lilly's Insulin Lispro Injection. To learn more about Lilly's Non-Branded Insulins, call the Lilly Diabetes Solution Center at **1-833-808-1234, M-F, 9 am-8 pm, ET.**

Discount Programs

Blink Health and Inside Rx are independent third-party programs that may offer you discounts of up to 50% on insulin compared to what you are paying at the pharmacy. You can obtain information at: <https://www.insulinaffordability.com/discount-programs.html>.

Savings Cards

People with diabetes may qualify for savings cards to help with the cost of certain Lilly insulins and diabetes medicines. (Basaglar, Humalog 200units/ml KwikPen, and Humulin R U-500) You can obtain information at: <https://www.insulinaffordability.com/savings-cards.html>.

Lilly Product Donations

Eli Lilly and Company donates product, including insulin, to charitable organizations such as Americares, Direct Relief, Dispensary of Hope, and the Lilly Cares Foundation (www.lillycares.com) that provide free Lilly medication for patients who meet each charitable organization's program eligibility requirements. The specific eligibility requirements and associated benefits of each charitable organization's program may differ from the eligibility requirements and benefits of the Minnesota Insulin Safety Net Program. Information regarding charitable organizations receiving Lilly insulin donations may be obtained from the Lilly Diabetes Solution Center at **1-833-808-1234, M-F, 9 am-8 pm, ET.**

Novo Nordisk

Novo Nordisk has provided the Board with the following information concerning their

Minnesota continuing need program:

- A patient - or a prescriber or MNSure Navigator helping the patient - may apply to the Novo Nordisk Patient Assistance Program (PAP) by completing the Application Form found at: <https://www.novocare.com/diabetes-overview/let-us-help/pap.html> and submitting it along with the supporting documentation. The patient, prescriber or MNSure Navigator may also call 1-866-310-7549 with program-related questions.
 - If you have insurance that requires you to pay more than \$75 out-of-pocket for a 30-day supply of insulin, ***you can still fill out the application*** – even though the application states that you can't be insured. Novo Nordisk ***will*** verify eligibility for MN residents enrolled in insurance plans that provide prescription drug coverage.
 - Patients will be notified of the decision on their application by a phone call to the contact telephone number listed on the PAP Application and a letter mailed to the address listed on their application form. In addition, a patient's prescriber will also receive a copy of the letter.
 - Once approved, patients will receive a 120-day supply of insulin medication shipped directly to their residence.
 - Patients denied eligibility to PAP will be provided a denial reason and directed to visit www.NovoCare.com or to call 1-844-NOVO4ME to learn about other potential financial assistance offerings available. Patients or their prescribers may also call 1-866-310-7549 to inquire about the status of their PAP application.

In addition to the program that Novo Nordisk has created for the Minnesota Insulin Safety Net Program, it offers the following assistance:

NovoCare Patient Assistance Program (PAP)

This program provides medication at no cost to those who qualify. There is no registration charge or monthly fee for participating. To qualify, you have to meet the following requirements:

- Be a US citizen or legal resident.

- Have a total household income is at or below 400% of FPG (See above for an FPG income table).
- have no insurance, or have Medicare
- Not be enrolled in and don't qualify for any other federal, state, or government program such as Medicaid, Low Income Subsidy, or Veterans (VA) Benefits.
 - Exceptions include people who are Medicaid eligible who have applied for and been denied Medicaid

For persons affected by COVID-19 job loss. *If you have lost your health insurance coverage because of a change in job status due to COVID-19, you may be eligible for a free 90-day supply of insulin.*

Documentation required for those affected by COVID-19:

- Completed PAP application
- Documentation showing loss of healthcare benefits (job termination notice, job status change, proof that COBRA benefits being offered)
- No proof of income required

If approved, you will receive a free 90-day supply of insulin. Novo Nordisk will check back with you (before your 90-day enrollment ends) to determine continued eligibility. Assistance can be extended to the end of 2020 for otherwise eligible patients who have been denied Medicaid coverage.

Instructions for applying for the PAP can be found at: <https://www.novocare.com/diabetes-overview/let-us-help/pap.html>

Savings Cards

If you have private or commercial insurance, such as insurance you receive through an employer or purchase yourself, you may be eligible to save on your Novo Nordisk diabetes medicine – through the use of savings cards. Novo Nordisk offers savings cards for Fiasp, Levemir, NovoLog, NovoLog Mix 70/30, Tresiba, and Xultophy. Depending on the drug, you may be able to pay as little as \$5 - \$45 per 30-day supply, for up to 24 months.

To learn more about Novo Nordisk assistance programs visit:

<https://www.novocare.com/diabetes-overview/let-us-help/help-with-insulin-costs.html>

Sanofi

Sanofi has provided the Board with the following information concerning their Minnesota continuing need program:



MINNESOTA CONTINUING SAFETY NET PROGRAM for Sanofi Insulins Patient Information Sheet

The Alec Smith Insulin Affordability Act (the "Act"), effective as of July 1, 2020, mandates that insulin manufacturers create a Continuing Safety Net Program (the "Program") to provide free insulin to Minnesota (MN) residents who meet certain specified eligibility criteria. Sanofi is administering the MN Continuing Safety Net Program through Sanofi Patient Connection®, a patient assistance program that helps patients get access to their medications.

What are the eligibility criteria mandated by the Act?

In order to be eligible for this Program, Minnesota requires you to meet the following requirements:

- You must be a resident of the State of Minnesota (MN) with a valid Minnesota identification card that indicates MN residency in the form of a MN identification card, driver's license or permit, or tribal identification card.
- You must not be enrolled in medical assistance or MinnesotaCare.
- You must not be enrolled in prescription drug coverage through an individual or group health plan that limits the total amount of cost-sharing that an enrollee is required to pay for a 30-day supply of insulin, including co-payments, deductibles, or coinsurance to \$75 or less, regardless of the type or amount of insulin needed.
- You must have an annual household income of $\leq 400\%$ of the current Federal Poverty Level.
- You must not be eligible to receive health care through a federally funded program or receive prescription drug benefits through the Department of Veterans Affairs; and
- If you are enrolled in Medicare Part D, in addition to the criteria above, you must also spend at least \$1,000 of your annual household income on prescription medications covered through your Part D plan in the current calendar year.
- You must also be under the care of a licensed healthcare provider authorized to prescribe, dispense and administer medicine in the U.S.

What insulins are available through the Program?

Sanofi offers the following four insulins that would be available for you under the Program: Admelog® (*insulin lispro injection*) 100 Units/mL, Apidra® (*insulin glulisine injection*) 100 Units/ml, Lantus® (*insulin glargine injection*) 100 Units/mL, and Toujeo® (*insulin glargine injection*) 300 units/mL.

How do I apply?


In order to apply for the Program, you must complete the Minnesota Continuing Safety Net Program application which can be found at www.sanofipatientconnection.com.

For additional information, you can call 866-489-5957.

What happens next?

Once we receive your application and proof of MN residency, we will notify you within 5-7 business days if we require additional information to process your application, or we will begin the review process to confirm you meet the eligibility criteria. If you are eligible, you and your healthcare provider will receive a letter within 10 business days notifying you of enrollment. You will be enrolled for 12 months. *(Note: If you are a Medicare Part D patient, you will be enrolled through the end of the calendar year, and your eligibility is renewable upon a redetermination of eligibility.)* Your medication will be sent directly to your home in approximately 5-7 business days from when you are approved.

If you do not qualify for the Program, we will send you and your healthcare provider a letter within 10 business days with the reason for denial.



The screenshot shows the Sanofi Patient Connection website. At the top right is the SANOFI logo. Below it is a navigation bar with 'English', 'Español', 'For U.S. Healthcare Professionals', and 'For U.S. Residents Only' buttons, along with a search bar. A main navigation menu includes 'Home', 'Patient Assistance Connection', 'Medications Available', 'Reimbursement Connection', 'Resource Connection', 'Online Resources', and 'FAQs'. The main content area features a large image of a smiling woman and the heading 'Patient Assistance Connection'. Below this is a button 'See if you may qualify' and the text 'Find out if you're eligible to receive your prescription medication at no cost.' At the bottom, there are three columns: 'Sanofi Patient Connection® Application' with a 'Download Application' button, 'Frequently Asked Questions' with a 'See FAQs' button, and 'Savings Program' with a 'See Savings' button.

In addition to the program that Sanofi has created for the Minnesota Insulin Safety Net Program, it offers the following assistance:

Sanofi Patient Connection – Patient Assistance Program (SPC PAP)

The SPC PAP currently offers free drug to qualified low- and middle-income patients. The eligibility criteria include:

- You must be a resident of the U.S. or U.S. Territories and be under the care of a licensed healthcare provider authorized to prescribe, dispense and administer medicine in the U.S. or U.S. territories
- You must have no commercial insurance coverage or access to the prescribed product or treatment via your insurance
- You must have an annual household income of $\leq 400\%$ of the current Federal Poverty Level. If you may be eligible for Medicaid, you will be required to provide documentation of Medicaid denial before being assessed for patient assistance eligibility
- If you are enrolled in Medicare Part D, in addition to the criteria above, you must also spend at least 2% of your annual household income on prescription medications covered through your Part D plan in the current calendar year

You need to fill out an application.

www.sanofipatientconnection.com/media/pdf/SPC_Application.pdf

Sanofi's vendor processes the application and determines eligibility. If approved, you are eligible for up to 12 months of assistance. If longer assistance is required, you can reapply on a yearly basis. Per federal regulations, Medicare Part D patients that are approved will qualify for assistance through the end of the calendar year and will be transitioned back to Medicare Part D at the beginning of each calendar year. Medicare Part D patients can reapply on a yearly basis and will be reapproved provided that they continue to meet the above eligibility criteria. A 90-day supply of your prescription is shipped directly to your prescriber's office.

Copay Programs for Sanofi Insulin Products

- Copay offers are available through the following channels:
 - Sales rep leaves physical cards (that require activation) at doctors' offices for doctors to give to patients; activation of these cards prompt patients to answer eligibility criteria questions;
 - Product Websites - prompt patients to answer eligibility criteria questions; if patient meets eligibility criteria, they can download a PDF of their savings card immediately;

- <https://www.lantus.com/sign-up/savings-and-support>
 - <https://www.apidra.com/savings>
 - <https://www.toujeo.com/toujeo-savings-card-coupon-and-support>
 - <https://www.admelog.com/savings>
 - Phone Number (IVR and Live Agent)
- Eligibility Criteria
 - Patient must be a resident of the United States, Puerto Rico, Guam, or US Virgin Islands
 - Patient must be 18 years of age or older to enroll
 - If a caregiver is facilitating enrollment on behalf of a minor patient (under 18 years old) in the program, the caregiver must be 18 years of age or older to enroll
 - Per federal regulations, Sanofi Copay Card Programs are not valid for prescriptions covered by or submitted for reimbursement under Medicaid, Medicare, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program.
- Copay Offer
 - Lantus Copay Program
 - Program offers eligible commercially insured Lantus patients to pay as low as \$0 copay and not more than \$99 copay, per 30-day supply.
 - Toujeo Copay Program
 - Program offers eligible commercially insured Toujeo patients pay as low as \$0 copay and not more than \$99 copay, per 30-day supply.
 - Apidra Copay Program
 - Program offers \$0 copay with maximum savings up to \$100 per monthly prescription
- Insulins ValYou Savings Program
 - Program offers patients without prescription medication insurance who are paying cash for their prescriptions to pay \$99 for their monthly supply of any one or combination of Sanofi Insulins
 - Maximum of up to ten 10mL vials or packs of pens per fill
 - Sanofi insulins included in this program include Admelog®, Apidra®, Lantus® and Toujeo® (Toujeo Max Solostar pen is excluded).

Patients can apply on their prescribed products' website or at InsulinsValyou.com